Objective: Intravaginal exposure to simian immunodeficiency virus (SIV) acutely recruits interferon-alpha (IFN-α) producing plasmacytoid dendritic cells (pDC) and CD4 + T-lymphocyte targets to the endocervix of nonhuman primates. We tested the impact of repeated cervicovaginal exposures to noninfectious, defective SIV particles over 72 hours on a subsequent cervicovaginal challenge with replication competent SIV. Methods: Thirty-four female Indian Rhesus macaques were given a 3-day twice-daily vaginal exposures to either SIVsmB7, a replication deficient derivative of SIVsmH3 produced by a T lymphoblast CEMx174 cell clone (n = 16), or to CEM supernatant controls (n = 18). On the fourth day, animals were either euthanized to assess cervicovaginal immune cell infiltration or intravaginally challenged with SIVmac251. Challenged animals were tracked for plasma viral load and CD4 counts and euthanized at 42 days after infection. Results: At the time of challenge, macaques exposed to SIVsmB7, had higher levels of cervical CD123 pDCs (P = 0.032) and CD4 + T cells (P = 0.036) than those exposed to CEM control. Vaginal tissues showed a significant increase in CD4 + T-cell infiltrates (P = 0.048) and a trend toward increased CD68 + cellular infiltrates. After challenge, 12 SIVsmB7-treated macaques showed 2.5-fold greater daily rate of CD4 decline (P = 0.0408), and viral load rise (P = 0.0036) as compared with 12 control animals. Conclusions: Repeated nonproductive exposure to viral particles within a short daily time frame did not protect against infection despite pDC recruitment, resulting instead in an accelerated CD4 + T-cell loss with an increased rate of viral replication.
Introduction
Women comprise over half of all individuals living with HIV-1 worldwide with intravaginal sex as the predominant route of transmission. 1 However, the rate of infection among exposed females is statistically low, indicating that only a fraction of viral exposures result in productive infection. [2] [3] [4] [5] At each exposure, HIV can interact with the cervical epithelium 6, 7 mediating cellular infiltration 6, 8 and potentially engaging Toll-like receptor (TLR) 7 on dendritic cells. [8] [9] [10] The effects of nonproductive HIV-1 or simian immunodeficiency virus (SIV) cervicovaginal exposures (absent infection) on subsequent infection outcomes remain unclear.
The CAPRISA004 trial found a positive association between a preexisting inflammatory cytokine profile within cervicovaginal fluids and subsequent HIV infection, 11 supporting previously held views that vaginal immune activation increases HIV-1 infectivity. In parallel, a study examining SIV infectivity in rhesus macaques after direct topical application of TLR-7/9 ligands to the cervicovaginal mucosa showed increased localized inflammation and increased viral load after challenge. 12 However, there are well-documented cases of women with a history of chronic multiyear HIV-1 exposure without infection indicating that exposure-initiated mechanisms may reduce future infectivity on reexposure. [13] [14] [15] Of interest, studies of resistance in these women have largely failed to identify HIV-specific responses as a determinant of protection 15 but a loss of HIV-1 "resistance" in a subset of these women after reduced sex work (i.e., HIV-1 exposure) has suggested that resistance is sustained by innate rather than adaptive responses. 16 Acute cellular changes after cervicovaginal mucosal infection have been studied. Infection is established within CD4 + T cells and other permissive cells of the lamina propria [17] [18] [19] [20] following a robust cellular infiltrate of plasmacytoid dendritic cells (pDCs) and CD4 T cells, 6 and increased mRNA expression of proinflammatory cytokines/chemokines by day 3 post infection (DPI). 21 Of interest, Li et al. demonstrated that infiltrating cervical pDCs produce interferon-alpha (IFN-α) within hours of SIV exposure, preceding CD4 + T-cell infiltrates by 72 hours. 6 The anti-HIV properties of pDCs and type I IFN have been documented and involve intrinsic and secondary antiviral mechanisms, such as the induction of tetherin or APOP-BEC family members, and the modulation of innate and adaptive effectors. [22] [23] [24] [25] [26] [27] In a recent clinical study in individuals with chronic HIV infection, IFN immunotherapy sustained viral suppression during antiretroviral therapy interruption in a subset of subjects supporting the interpretation that IFN can inhibit HIV-1 production/replication. 28 However, the role of infiltrating pDCs as a source of type I IFNs and its impact on acute SIV infection if present before infection as a result of repeated noninfectious viral exposures remains unclear. Taking advantage of a replication-deficient SIVsmB7 clone derived from SIVsmH3, able to bind CD4 and fuse with its target without subsequent viral replication, [29] [30] [31] we tested the hypothesis that repeated vaginal exposures to SIV in the absence of productive infection would decrease viral infection potential and/or decrease replication kinetics as a consequence of sustained cervical pDC infiltration despite the increase in local CD4 + T-cell infiltrates.
Methods

Ethics Statement and Animal Procedures
Healthy Indian Rhesus monkeys (Macaca mulata) were acquired from the Caribbean Primate Research Center of the University of Puerto Rico (UPR)-Medical Sciences Campus (MSC). Animals were quarantined for 6 months and maintained at the AAALAC-accredited facilities of the Animal Resources Center, UPR-MSC.
All animal studies were approved by the UPR-MSC, Institutional Animal Care and Use Committee (IACUC), and comply with the Guide for the Care and Use of Laboratory Animals. Animal Welfare Assurance number: A3421, Protocol number: 3380308.
In addition, steps were taken to reduce suffering in accordance with the recommendations of the Weatherall report, "The Use of Nonhuman Primates in Research." For instance, all procedures were conducted under anesthesia by using ketamine 10-20 mg/kg, delivered intramuscular.
Phase I: 10 (6 and 4) macaques were given either intravaginal SIVsmB7 or CEM mock control inoculations. Inoculations were given twice daily for 3 days in either the follicular or luteal phase, as shown in figure 1 and figure S1 (see the supplemental content following the references). Macaques were euthanized on the fourth day. Figure 1 . Phase I/II criteria. The study was separated into 2 separate phases. Ten macaques were used in phase I: 4 CEM mock control intravaginally inoculated animals and 6 SIVsmB7 intravaginally inoculated animals. These animals were used to assess cellular infiltration in the cervical and vaginal epithelium. For phase II, 24 animals were divided equally either into CEM mock control-or SIVsmB7-inoculated animals. The inoculation sequence for phase I was repeated and SIVmac251 challenge.
Phase II: Female macaques were housed together before use in the study to allow the animals to reach menstrual synchrony. Twenty-four macaques, 12 macaques per group, were given either intravaginal SIVsmB7 or CEM mock control inoculations (table 1 and fig.  1 ). Inoculations were given twice daily for 3 days during the luteal phase. On the fourth day after inoculation, each macaque was given a single 1 mL challenge dose SIVmac251. Blood was taken before the challenge and on days 7, 14, 21, and 42 to determine plasma viral load and CD4 count. Macaques were euthanized on days [42] [43] [44] [45] [46] based on the analysis focused on early viral kinetics after a single exposure and infection. Euthanasia was performed only on fully anesthetized animals by injection of pentobarbital sodium at 390 mg/mL; 1 cc/10 lbs IV. Vaginal and cervical tissues were taken for analysis.
Viruses
SIVmac251 was diluted 1:2 from a 20,000 TCID50 per milliliter viral stock grown in specific pathogen free rhesus macaque peripheral blood mononuclear cell produced by Dr. Ron Desrosiers (New England National Primate Research Center, Harvard Medical School) and kindly provided by Dr. Nancy Miller (NIAID) through contract #N01-AI-30018. Animals were challenged with 1 mL of the diluted viral stock. In vivo, titration was performed as described in the Supplemental Methods.
SIVsmB7 is a virus-like particle derived from a clone of a CEMx174 cell line stably infected with SIVsmH3. SIVsmB7 is noninfectious because of a 1.6 kbp deletion, including integrase, vif, vpr, and vpx genes. Cell-free SIVsmB7 and CEMx174 supernatant (CEM mock control) were isolated by standard 20% (wt/vol) sucrose gradient ultracentrifugation. P27 enzyme-linked immunosorbent assay was used to determine 500 µg P27 SIVsmB7 dose. CEMx174 dose was established by equal protein quantification with SIVsmB7 dose.
CD4 and CD8 Counts
CD4 and CD8 counts were monitored by TruCount Absolute Count Kits (BD Bioscience, San Jose, California) used according to manufacture protocol.
SIV Viral Loads
Plasma viral load was assessed by quantitative reverse transcriptase-polymerase chain reaction as previously described. 32 Full method can be found in the Supplemental Methods. Immunohistochemistry Samples from the vagina and cervix were harvested postmortem from each animal and fixed in 4% paraformaldehyde and embedded in paraffin for sectioning, SafeFix II (Fisher Scientific, Pittsburgh, PA), or frozen. Immunohistochemical staining for CD123, CD68, CD4, and Mx1 was conducted as previously reported6 (For complete method, see Supplemental Methods, http://links.lww.com/QAI/A482). CD123 + cells were considered pDC as a previous report by Li et al6 has shown that CD123 + cells infiltrating into the endocervical subepithelium 3 days after SIV exposure stain positive for both HLA-DR and IFN-α confirming these cells are pDC.
Statistical Analysis
Cross-sectional phase 1 and phase 2 two group comparisons between SIVsmB7-exposed and CEM mock control-inoculated animals were made using Wilcoxon rank-sum tests, Fisher test or Student t tests. Two-tailed P values less than 0.05 were considered statistically significant.
To evaluate the rate of change for LogVL and CD4, a change-point model with random intercept terms for each monkey and fixed effects for baseline CD4, days-postinfection (DPI) (overall and after 14 DPI), a group indicator for SIVsmB7 exposure, and 2-way interaction terms between DPI and group, was fitted. This model accounts for the within individual correlation in repeated measurements and allows for a different slope before and after 14 DPI. The models are listed below, with model variables estimates described in the results. The function (DPI-14) + = 0 when DPI ≤ 14 and (DPI-14) + = DPI-14 when DPI > 14.
Model Equations for SIVsmB7 or CEM-Inoculated Animals
Statistical analysis was performed using R 2.14.1 and Prism.
Results
Phase I: Acute Cellular Infiltrates after 72 Hours of SIVsmB7/CEM Mock Control Exposure Ten female macaques followed during their natural luteal or follicular phases were used to initiate 3-day twice-daily SIVsmB7/CEM mock control dosing within a 3-day period after the start of a menstrual phase (as exemplified for 2 luteal-staged animals in fig. S1 in the supplemental content). Animals were inoculated with CEM mock or SIVsmB7 as described in figure 1 and in the methods.
Consistent with previously published data showing that infectious SIV exposure resulted in acute endocervical pDC and CD4 + T-cell infiltration within 3 days of SIV exposure/infection, 6 replication-deficient SIVsmB7-treated animals had a significant higher number of endocervical CD123 + pDC (P = 0.0317, mean: 1328 cells/mm 2 . Similar to pDCs, SIVsmB7-treated animals had higher (although not statistically significant) levels of CD68 macrophages than control animals in the cervix, but not in the vaginal tissue. Altogether, results confirm that exposure to replication-deficient SIV can modulate the tissue microenvironment, allowing us to directly test how these local viral-induced changes (i.e., pDC and CD4 T-cell infiltrates) would impact a challenge with infectious SIVmac251. 
Phase II: Outcome of SIVmac 251 Infection after 72-Hour Preconditioning with SIVsmB7 or CEM Control
Twenty-four female macaques were challenged with SIVmac251 after undergoing 72-hour exposure (as described above) to either SIVsmB7 (n = 12) or CEM control (n = 12). The groups were similar in weight and inoculation date relative to menstrual cycle (table 1; see fig. S2 in the supplemental content), and there was no significant difference in major histocompatibility complex (MHC) class I allele distribution (Fisher exact test, P > 0.05) or for those associated with spontaneous control between groups [33] [34] [35] (see table S1 in the supplemental content).
Endogenous estrogen levels at the time of challenge between SIVsmB7 and CEM mock control arms were not significantly different (P = 0.84) (table 1), indicating the absence of differences in estrogen-related structural epithelial factors known to impact viral infectivity. [36] [37] [38] As it has been shown that cervicovaginal inflammation is common among captive rhesus macaques, 39 a 28-plex nonhuman primate luminex assay was performed within 1 week of challenge to assess levels of proinflammatory mediators in cervicovaginal lavages (CVL) in 13 of the 24 macaques (6 SIVsmB7/7 CEM mock). Twelve of the cytokines/chemokines tested were below the limit of detection and no cytokine/chemokine tested showed any significant difference between groups. Results for selected cytokines and chemokines are summarized in figure S3 (see supplemental content) .
Following a single, intravaginal SIVmac251 challenge using an infectious dose previously determined through an intravaginal titration (see Supplemental Methods), all 24 macaques became infected, with a detectable viral load within 7 or 14 days postinfection (DPI) ( fig. 3B ). Viral load peaked in all animals by 14-21 DPI, with a mean viral load of 6.63 and 8.02 for CEM mock control-and SIVsmB7-treated, respectively (Student t test: P = 0.0720).
Although we didn't detect a significant difference in peak viral load, there was a trend toward increased viral load in SIVsmB7-treated macaques as compared with CEM mocktreated animals ( fig. 3B) . We did detect a statistically significant decline in CD4 + T cells at 14 DPI in SIVsmB7-treated macaques as compared with control animals (Student t test: P = 0.0268, mean: -355.8 CD4/µl vs. CEM-120.4 CD4/µl) ( fig. 3D ) consistent with a more severe CD4 depletion after infection in the SIVsmB7-treated females. Notably, 4 of the macaques in the control group (animals 8D4, M847, 31R, and 530) had lower plasma viral loads. These animals were similar to the other animals in the control and experimental groups in terms of MHC genotypes, batch of doses used, day of manipulation, estrogen levels, weight, age, and history of parity (data not shown). Analysis of baseline CVL samples from 2 of these macaques, 53O and 31R, showed no difference to other infected control macaques. Figure 3 . Change-point model of log plasma viral load (LogVL) and CD4 for phase II macaques. A, ∆CD4 for SIVsmB7-treated macaques was significantly higher than in CEM mock control. By 14 DPI, there was mean loss of -355.8 CD4 per microliter in SIVsmB7-treated animals compared with -120.4 CD4 per microliter for controls [Student t test; P = 0.0268 (inset)]. B, Twenty-two of 24 macaques in both treatment arms reached peak viral load on days 14 or 21. Four of the CEM macaques had significantly lower log viral loads than the remaining 8 CEM mock macaques (t test on area under curve with P < 0.0001), which was not explained by known correlates of spontaneous SIV control or protection suggesting low viral load was normal variation. At no time point was difference in Log viral load significant; however, starting at 14 DPI and ending at 42 DPI, there was a trend toward increased viremia in SIVsmB7-inoculated macaques (Student t test; P = 0.118). C, As we detected a significant difference in ∆CD4 between groups, we generated a linear mixed effect spline model to investigate CD4 change between treatment groups over time (in days, as "DPI"). This model predicts an increased loss of CD4 + T cells per day of 14.5 cells per microliter over top of the CEM mock control animals culminating at peak viremia (day 14). D, To investigate the behavior of log viral load, a linear mixed effect spline model for LogVL was also generated. The LogVL model predicts SIVsmB7-treated animals to have an increased log viral load rise per day of 0.106 over top of CEM mock-treated animals up until peak viremia on day 14.
Model of Log Viral Load Rise and CD4 Decline in Phase II Macaques
As our data detected that SIVsmB7 exposures before an infectious challenge caused a significant decline in CD4 at peak viral load after infection, we generated linear models for CD4 or log viral load kinetics over days (DPI) and included a spline (or change-point) at peak viral load day 14 representing the end of the acute change in variables after infection (illustrated in both viral load and CD4 decline data in figs. 3C, D). As expected, both models showed that (1) DPI is a significant determinant of both CD4 decline and viral load rise for animals in either group as exemplified by its coefficient β3 in control (P = 0.0436 for CD4 and P < 0.0001 for logVL; Methods and table 2) and β3′ in SIVsmB7 treated (P = 0.0408 for CD4 and P = 0.0036 for logVL) and (2) day 14 is a valid change-point as illustrated by the reverse of direction of estimates for β3 and β4 for the control and β3′ and β4′ for the SIVsmB7 group.
The model for CD4 T-cell kinetics closely approximated our CD4 data and indicated a significantly different change rate between groups before day 14 (β3′, P = 0.0408; fig. 3 and table 2). The effect of infection in the CEM mock control animals showed a loss of 10.06 CD4 + T cells per microliter each day until peak viremia (140.8 loss at peak viral load). SIVsmB7-treated macaques had a 2.5-fold higher daily loss of CD4 + T cells totaling 25.0 CD4 + T cells per microliter per day (342.8 loss at peak viral load).
As for viral load, the model showed a significantly higher rate of change in viral load for the SIVsmB7 over CEM control before day 14 (β3′, P = 0.0036; fig. 3 and table 2) in support of greater CD4 T-cell loss. Specifically, log viral load rise each day after infection was predicted to be 0.553 log per day in SIVsmB7-treated macaques as compared with 0.446 log per day for CEM mock control animals. Taking into account baseline CD4 count, CD8 count, CD4/CD8 ratio, age, or weight, as independent factors did not change the model's output for viral load rise.
All together, our results suggest that noninfectious SIV exposures and associated conditioning of the local microenvironment result in a greater CD4 + T-cell decline with higher viral load. 
Discussion
We show for the first time that an early, local, innate, and CD4 T-cell response to replication-deficient SIV particles can enhance the rate of CD4 + T-cell decline and viral load rise on a subsequent productive infection. Our results were contrary to our original hypothesis that the observed increase in SIV-induced cervical pDC infiltrates and local IFN-mediated mechanisms would inhibit productive infection. Instead, our data are consistent with viral exposures acutely modulating levels of vaginal and cervical CD4 + T-cell infiltrates, providing a greater preexisting "substrate" for viral infection, potentially overwhelming any inhibition provided by pDC and resulting in an accelerated decrease of CD4 + T cells in association with viral replication. Importantly, our data assessing the impact of recruited pDC were collected during natural progesterone high periods independent of pharmacological treatments commonly used to synchronize animals as these have been shown to impair pDC function. 40, 41 Our results parallel a report by Wang et al. where female macaques were preexposed to TLR-9 or TLR-7 ligands, CpG, or imiquimod, respectively, before and during SIVmac251 challenge. 12 Wang et al. did not quantify differences in cellular infiltrates before challenge nor model viral kinetics to peak viral load, but did observe increased inflammatory cytokines and infiltrate after dosing and a higher viral load 8 weeks after infection. Their reported data are consistent with our observed accelerated CD4 loss and viral load rise in SIVsmB7 pre-exposed animals. We speculate that the Wang et al. study showed a more marked increase in viral replication than our study due to use to 2 challenges using a SIVmac251 one log higher (greater viral inoculum42) and use of optimized TLR-7/9 ligands, which may have induced a greater inflammatory environment (greater local immune activation 43 ).
Importantly, our results are directly relevant to both low-dose SIV repeated challenge study designs commonly used in vaccine studies and to settings of repeated HIV exposures in women. Regarding SIV study designs, our data suggest that early SIV challenges may encounter a different microenvironment than later challenges as a result of immune cell infiltration. Infections after repeated exposures may increase local cell targets and result in accelerated infection kinetics and/or greater gut-associated lymphoid tissue depletion when compared with infections occurring at the start of exposures. Per human cohorts, our data suggest that a sex worker in an area with high HIV-1 prevalence may have different levels of intravaginal immune cell infiltration, independent of coinfections, as compared with women with low levels of HIV-1 exposure. The presence of increased CD4 + T cells and CD68 cells in women at higher risk of HIV-1 infection or in nonhuman primates after multiple SIV exposures may decrease the efficiency of prophylactic interventions by increasing infection efficiency. However, it would be of interest to determine if vaccineelicited antiviral antibodies in the presence of an increase in cellular infiltration could also provide a greater effector population to harness potentially protective antibody-depended cell-mediated cytotoxicity mechanisms in high-risk uninfected women. Taken together, our data suggest that SIV/HIV exposures can contribute to local immune modulation affecting the host tissue response to future viral infection as already established for other STD coinfections. 4, 16, 44, 45 Future experiments using a lower infectious dose or repeated low to high-dose escalation of virus would be needed to directly show if SIVsmB7 preexposures would increase infection rate over controls as suggested by our data.
Our study had limitations that we addressed. First, our replication-deficient virus, SIVsmB7, was derived from the human cell line, CEMx174. Previous studies have shown that xeno/allogeneic adaptive immune responses to MHC alone can block infection. 46 We found that both SIVsmB7 and CEMx174 supernatants had MHC class I and class II proteins (see fig. S4 in the supplemental content). The 72-hours time frame used for this experiment would limit development of adaptive xenoantigenic responses; moreover, we used a challenge virus derived from a rhesus macaque cell line to avoid this possible confounder response (Methods). It has been shown that innate allogenic responses can be rapid in response to live tissue grafts, 47 yet little is known about the speed and strength of such responses through mucosal administration of MHC proteins. Mucosal studies to date have only examined such responses after the induction of the adaptive response. 48, 49 We interpret that because MHC proteins are present in both SIVsmB7 and control, it is unlikely there would be a differential response yet to be detected based on MHC alone. Importantly, CD4 + T-cell and pDC infiltration was significantly greater in SIVsmB7-treated animals indicating the control proteins did not induce change in the absence of SIV proteins. As for other proteins shown in figure S4 and table S2 (see the supplemental content), proteomic analysis of both CEM mock and SIVsmB7 doses had comparable protein content to SIVsmB7 outside the presence of viral proteins or Mov10. Interestingly, the presence of Mov10 (see table S2 in the supplemental content) in SIVsmB7 proteomic analysis is consistent with enriched particle generation, as previous reports have shown that Mov10 incorporates into viral particles. 50 It has also been shown that ectopic expression of Mov10 is an inhibitor of HIV-1/SIV infectivity [50] [51] [52] [53] ; however, our data together with a recent report showing that basal levels of Mov10 had no impact on HIV-1 replication or infectivity argues against its antiviral potential. 51 Second, previous studies have shown that captive rhesus macaques can have divergent preexisting cervicovaginal inflammation. 39, 54 To control for this, we did random testing of CVL from rhesus macaques and found no difference in inflammatory cytokine levels between treatment groups (see fig. S3 in the supplemental content) despite observing differential CD4 changes between groups as described. The only difference we did detect was a 1-year difference in age between groups (table 1). We do not expect this minor difference impacts our data as previous research has evidenced no significant difference in immune parameters, such as immune activation or serum cytokine level, among young to middleage macaques. 55 Third, our conclusions address the cervicovaginal mucosa and not other mucosal routes of exposure. Future studies will need to establish whether repeated replication-deficient rectal exposures induce CD4 + T-cell infiltration and affect the severity of a productive infection. Intriguingly, sustained SIV-resistance has been reported following repeated lowdose intra-rectal SIV challenges, highlighting a potential difference in compartments or difference between 72 hours versus chronic exposure effects or both. 56 In conclusion, our data support a model where viral exposures in the absence of productive infection induce changes in cervicovaginal cellular infiltrates that do not prevent infection. Furthermore, our data may indicate an added risk to repeated short-term exposures not previously identified and introduces an unaccounted tissue change variable that may impact the outcome of SIV challenge in studies evaluating protection by low-dose repeated challenge formats using female macaques. 
Supplemental Digital Content -Methods
SIVsmB7 and CEMx174 Proteomic Analysis
SDS-PAGE Gels 20 µl of B7 and CEM each were loaded to a 12% NuPage 1-mm-thick gel. The gel was stained with Invitrogen Colloidal Coomassie Blue stain.
Protein Digestion
Selected bands were excised from the gel and subsequently destained using 200 µl of 200 mM ammonium bicarbonate and 50% acetonitrile for 30 min with shaking at 37°C and then dried in a SpeedVac. This was followed by reduction/alkylation of the protein band by adding 100 µl 20 mM TCEP in 25 mM ammonium bicarbonate at pH 8.0, incubated for 15 min at 37°C with shaking. The supernatant was discarded and 100 µl of 40 mM iodoacetamide in 25 mM ammonium bicarbonate at pH 8.0 was added and incubated for 30 min at 37°C with shaking. The supernatant was again discarded and two subsequent washes of 200 µl 25 mM ammonium bicarbonate were done for 15 min each with shaking. A final wash was done under the same conditions, except 50% acetonitrile, 25 mM ammonium bicarbonate was used for the wash. The bands were dried in the SpeedVac and were then rehydrated with 20 µl of 0.02 µg/µl modified Trypsin (Promega) in 40 mM ammonium bicarbonate overnight with shaking at 37°C. The next morning, the supernatant was removed to a clean tube on ice and 20 µl of 40 mM ammonium bicarbonate was added to the gel piece for 30 min with shaking at 37°C. The supernatants were combined and 4 µl of neat acetic acid were added to stop the digest.
Protein Identification 4 µls of the combined digest were injected onto a nanocapillary reverse-phase column (selfpacked, New Objective 75 um column terminating in a nanospray 15 um tip) directly coupled to a ThermoElectron Orbitrap mass spectrometer. A top six method was used to obtain MS and MS/MS data. A customized database was created using a Simian database with common contaminants and bovine (tagged) added. The database was indexed for partial tryptic searching and the resulting masses and MS/MS spectra from the Orbitrap were searched against this database using the SEQUEST search engine [1, 2] . Subsequent data were filtered using 5 ppm, delta cN of 0.07. Results were reported as spectral counts.
Hormone Measurements
Blood was taken every other day between days 7-23 of the menstrual cycle. Estradiol and progesterone concentrations were measured by enzyme-amplified chemiluminescence (Immulite 1000, Siemens). The analytical limits of sensitivity of the estradiol and progesterone assays were 15 pg/mL (references range of 20-2,000 pg/mL) and 0.1 ng/mL (reference range of 0.2-40 ng/mL), respectively.
Immuno-histochemistry
Tissues were deparaffinized and rehydrated in deionized water. Heat-induced epitope retrieval was performed using the water-bath method (95-98°C for 10-20 min) in 10 mM sodium citrate, pH6.0 for CD123 detection (Sc-681, 1:2000, Santa Cruz Biotechnology Inc.), and Mx1 (1:3000, ProteinTech) and CD68 (KP1, 1:200, Dako). For CD4 detection (IF6, 1:60, Leica Microsystems), epitope retrieval was performed using high-pressure Decloaking Chamber (121°C for 35 sec, Biocare Medical) in 1 mM EDTA, pH 8.0, followed by cooling to room temperature. Tissue sections were blocked with SNIPER Blocking Reagent 5% Non-fat milk (Biocare Medical) for 1 hr at room temperature. Endogenous peroxidase was blocked with 3% (v/v) H2O2 in methanol TBS (pH7.4) 3% [v/v] for CD68, Mx1 and CD123, and 0.9% for CD4 detection). Primary antibodies were diluted in 10% SNIPER Blocking Reagent in TNB blocking buffer (Tris-HCl, pH7.5, 0.15M NaCl, 0.05% Tween 20 with 0.5 Dupont blocking reagent buffer) and incubated overnight at 4°C. After the primary antibody incubation, sections were washed and then incubated with mouse, goat, or rabbit polymer system reagents conjugated with either horseradish peroxidase or alkaline phosphatase (ENVISON kit; Dako) according to the manufacturer's instructions, and developed with 3,3′-diaminobenzidine (Vector Laboratories). Sections were hematoxylin counterstained, mounted in Permount (Fisher Scientific), and examined by light microscopy. Non-specific, IgG was used as isotypic control. Whole sections of each stained slide were digitized using Scanscope (Aperio), the image was opened in ImageScope, and endocervical areas were selected with ImageScope drawing tools for analysis. CD4+, CD68+, Mx1+ or CD123+ cells were quantified by using a positive pixel count algorithm in the Spectrum Plus analysis program (Version 9.1, Aperio). The parameters of the algorithm were manually tuned to match the specific staining markup image accurately over background DAB stain. Once the parameters were set, the algorithm was applied automatically to all digital slides to measure the number of cells of interest. Data were reported as positive staining cells per square millimeter.
DNA Isolation and MHC Genotyping
Genomic DNA was isolated from a maximum of 3.0 × 106 peripheral blood mononuclear cells using the MagNA Pure LC system (Roche Applied Science) and the MagNA Pure LC DNA Isolation-Large Volume protocol (version 3.0) according to manufacturer's guidelines. The elution volume of extracted DNA was 200 µl of MagNA Pure LC DNA IsolationLarge Volume elution buffer. DNA concentrations (ng/µl) and Abs 260 nm/Abs 280 nm ratios were determined using a NanoDrop UV Spectrophotometer (NanoDrop Technologies). Genotyping for Mamu-A*01, A*02, A*08, A*11, B*01, B* 03, B*04, B*17, B*08, and DRBw*201 was done as previously described [3] [4] [5] .
Viral Load
Plasma samples were spiked with armored RNA (aRNA; Asurgen) and centrifuged at 25,000 x g for 1 h. Viral RNA (vRNA) was extracted from the pellet with Proteinase K (2.5 µg/µl; Life Tech) and the High Pure Viral RNA kit (Roche). Eluted vRNA (100 µl) was then subjected to the RNA Clean and Concentrator kit (ZYMO Research) and eluted in 50 µl, from which 15 µl were reverse transcribed using MultiScribe™ Reverse Transcriptase (Life Tech) in a 50-µL gene-specific reaction. Fourteen microliters of cDNA were added to TaqMan gene expression master mix (Life Tech), along with primers and a probe targeting the gag region of SIVmac251, and subjected to 40 cycles of qPCR analyses. Fluorescence signals were detected with an Applied Biosystems 7900HT Sequence Detector. Data were captured and analyzed with Sequence Detector Software (Life Tech). Viral copy numbers were calculated by plotting CT values obtained from samples against a standard curve generated with in vitro-transcribed RNA representing known viral copy numbers. The limit of detection of the assay was five copies per reaction volume or 40 copies per ml of plasma.
SIVmac251 Titration
Infectious challenge was carried out with SIVmac251. The infectious dose via intravaginal delivery was independently determined in a titration study on 15 female rhesus macaques upon vaginal challenge preceding our study. Macaques were intravaginally inoculated with either a single dose of undiluted virus or a 1:5 or 1:10 dilution. All macaques given undiluted virus became infected. Thirty-eight percent of macaques given a 1:5 dilution became infected. To achieve a dose to infect all control animals a 1:2 dilution was chosen for the challenge dose. Figure S3 . Results from selected cytokines tested in CVL Cytokine Multiplex Assay. Luminex 28-plex Assay (Invitrogen) was done according to manufacturer protocol on PBS lavage samples obtained within 1 week prior to macaque manipulation. Nearly half of the inflammatory cytokines tested were below the level of detection. Of those with detectable levels of cytokine there was no significant differences between macaques, including inflammatory mediators IL-1b, IFNγ, and IL-17 and chemokines IL-8 and CCL22. P-values were generated by two-sided Wilcoxon rank sum tests. Method: SIVsmB7 is a virus-like particle (VLP) derived from a clone of a CEMx174 cell line infected with SIVsmH3 . Clone B7 cells have a single provirus integrated into their 20th chromosome. SIVsmB7 is noninfectious due to a 1.6 kbp deletion, including integrase, vif, vpr, and vpx genes [29] . To produce cell-free SIVsmB7 and CEM mock control, 200,000 cells/ml of Clone B7 and uninfected CEMx174 cells were cultured in RPMI 1640 (Mediatech, Inc.) supplemented with FBS. VLPs was purified on 20% (w/v) sucrose gradient by ultra-centrifugation. Figure 1B illustrates individual pellets from CEM mock control and SIVsmB7 after supernatants are removed. The pellet was resuspended in RPMI 1640 without supplementation. ELISA was done to measure P27 content. SIVsmB7 was diluted to a concentration of 500 µg P27 SIVsmB7 per 1 ml dose. CEMx174 dose was prepared using identical techniques. . As noted previously, SIV gag polyprotein was the dominant protein in each of those excised bands from SIVsmB7. The remaining proteins found in those bands were comparable to proteins identified from bands excised from CEM mock control taken from the same position in the CEM mock control lanes. Total coverage of the given protein is shown along with total spectral counts.
